iTeos Therapeutics Inc. (ITOS)
6.46
0.24 (3.86%)
At close: Apr 17, 2025, 3:59 PM
6.42
-0.65%
After-hours: Apr 17, 2025, 07:56 PM EDT
3.86% (1D)
| Bid | 5.5 |
| Market Cap | 246.74M |
| Revenue (ttm) | 35M |
| Net Income (ttm) | -134.41M |
| EPS (ttm) | -3.32 |
| PE Ratio (ttm) | -1.95 |
| Forward PE | -1.58 |
| Analyst | Buy |
| Ask | 7.65 |
| Volume | 891,242 |
| Avg. Volume (20D) | 329,418 |
| Open | 6.18 |
| Previous Close | 6.22 |
| Day's Range | 5.96 - 6.56 |
| 52-Week Range | 4.80 - 18.75 |
| Beta | 1.43 |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used t...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 173
Stock Exchange NASDAQ
Ticker Symbol ITOS
Analyst Forecast
According to 3 analyst ratings, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 163.16% from the latest price.
Stock ForecastsNext Earnings Release
iTeos Therapeutics Inc. is scheduled to release its earnings on May 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
-27.54%
iTeos Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
8 months ago
+10.13%
iTeos Therapeutics shares are trading higher after the company announced the oral presentation of Phase 2 GALAXIES Lung-201 interim data at the European Society for Medical Oncology Congress 2024
